Hyphens Pharma officially opens corporate headquarters and integrated facility

Download as PDF

Press Release 

  • Inked MOU with A*STAR’s A*ccelerate for R&D collaboration on dermatological products for skin disorders

Singapore, 21 May 2019 SGX Catalist-listed Hyphens Pharma International Limited (“凯帆药剂国际有限公司”, ”Hyphens Pharma”, or the “Company”, and together with its subsidiaries, the “Group”), one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups, officially opened its corporate headquarters and integrated facility today with Senior Minister of State for Trade and Industry, Dr Koh Poh Koon as Guest-of-Honour at the event.

Hyphens Pharma’s new corporate headquarters and integrated facility combines its prior four floors of operations across two separate buildings, into a single location. By consolidating its operations, Hyphens Pharma has improved the productivity, efficiency and teamwork amongst colleagues in different departments within the Group.

The integrated facility houses an automated packaging line that was designed in collaboration with Singapore Polytechnic’s Food Innovation and Resource Centre, while the warehousing space was designed in conjunction with Republic Polytechnic’s Centre of Innovation for Supply Chain Management to improve logistics efficiency.

Hyphens Pharma’s wholly-owned subsidiary, Hyphens Pharma Pte Ltd (“Hyphens Singapore”), has also entered into a memorandum of understanding (“MOU”) with Agency for Science, Technology and Research’s (“A*STAR”) commercialisation arm, A*ccelerate. Through past and ongoing collaborations, A*STAR and Hyphens Singapore have conducted various R&D activities such as product formulation, technology transfer and licensing, stability studies and in vitro and in vivo studies in the field of skin health. The latest MOU will build on prior partnership and further enhance the relationship between both organisations in R&D activities for dermatologicals and cosmeceuticals targeting eczema, acne and pigmentary disorders.

Executive Chairman and CEO, Mr Lim See Wah, (“林世华”) commented: “Our new corporate headquarters and integrated facility will not only provide enhanced efficiency and productivity, it will also serve as an oasis for our people to germinate creative and innovative ideas. We hope to grow our various business segments so as to achieve our objective of becoming a dominant ASEAN’s pharmaceutical & consumer healthcare group. Our collaboration with A*STAR through the MOU with A*ccelerate is a reflection of our commitment to grow through innovation. Together with the investment in our people, we aim for accelerated growth for the Group and its shareholders.”

Commenting on the MOU, Mr Philip Lim (“林峰”), CEO of A*ccelerate said: “This joint commercialisation partnership converges the technology strengths of A*STAR and industry capabilities of Hyphens Singapore in addressing unmet dermatological needs. Together, we aim to bring unique innovative products to the market as early as next year.”


About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the “Group”) is one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.

The Group’s core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

For more information, please visit

Issued on behalf of the Company by Cogent Communications Pte. Ltd.

For enquiries, please contact:
Ms Melissa Sim, Tel: (65) 6704-9287, Mob: (65) 9380-2938, Email: [email protected]
Mr Gerald Woon, Tel: (65) 6704-9268, Mob: (65) 9694-8364, Email: [email protected]

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. (“Sponsor”) for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (“the SGXST”). The SGX-ST and the Sponsor assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.